Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
August 07, 2023 at 04:01 pm EDT
Share
Enanta Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended June 30, 2023. For the third quarter, the company reported sales was USD 18.89 million compared to USD 19.48 million a year ago. Net loss was USD 39.07 million compared to USD 31.7 million a year ago. Basic loss per share from continuing operations was USD 1.86 compared to USD 1.53 a year ago. Diluted loss per share from continuing operations was USD 1.86 compared to USD 1.53 a year ago.
For the nine months, sales was USD 60.27 million compared to USD 65.84 million a year ago. Net loss was USD 105.71 million compared to USD 95.41 million a year ago. Basic loss per share from continuing operations was USD 5.05 compared to USD 4.64 a year ago. Diluted loss per share from continuing operations was USD 5.05 compared to USD 4.64 a year ago.
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).
ENANTA PHARMACEUTICALS, INC. 
